Therapeutic Goods (Medicinal Cannabis Products—Approvals and Authorities) (Information) Specification 2021

The instrument rests on a small set of statutory and technical concepts defined in the instrument itself or by cross-reference to the Act and Regulations. Understanding what the instrument does requires attention to those definitions and to the scope of the Secretary’s release power under s 61 of the Act, as invoked by the instrument.

Key concepts appearing in the instrument:

• Therapeutic goods information: The instrument refers to "therapeutic goods information" as defined in subsection 61(1) of the Act (clause 4). The instrument does not redefine that statutory meaning; it operates by selecting kinds of therapeutic goods information for release under the Act’s information-release regime (clause 5).
• Authorised prescriber authority and SAS B approval: The target products for the specified information are those "that are the subject of an authorised prescriber authority or a SAS B approval" (Schedule 1, Item 1). The instrument defines an "authorised prescriber authority" by reference to subsection 19(5) of the Act and a "SAS B approval" by reference to paragraph 19(1)(a) of the Act (clause 4). Those cross-references anchor the instrument to existing pathways through which unregistered or non-listed therapeutic goods can be supplied in Australia.
• Relevant category and categorical thresholds: The instrument creates five mutually exclusive "relevant category" classes for medicinal cannabis products (category 1 to category 5) and specifies precise cannabinoid composition thresholds for each. Each definition contains three parts: a percentage threshold for cannabidiol (CBD) or other cannabinoids (including tetrahydrocannabinol, THC), a threshold for the complementary cannabinoid fraction, and a requirement that the medicine contains no other active ingredients (clause 4, definitions of category 1-5). Examples:
  • Category 1: CBD comprises 98% or more of total cannabinoid content; other cannabinoids naturally found in cannabis 2% or less; no other active ingredients.
  • Category 3: CBD comprises 40% or more and less than 60% of total cannabinoid content; other cannabinoids (including THC) comprise remaining content; no other active ingredients.
  • Category 5: cannabinoids other than CBD (including THC) comprise more than 98% of total cannabinoid content; CBD <2%; no other active ingredient.
• Active ingredient, dosage form, product name, sponsor name: Schedule 1 identifies these specific data points as the kinds of therapeutic goods information that may be released in relation to covered medicinal cannabis products (Schedule 1, Item 1(a)-(e)). "Active ingredient" is stated to have "the same meaning as in the Regulations" (clause 4).
• Relation to the Regulations: The instrument expressly ties certain terms to the Therapeutic Goods Regulations 1990 (clause 4), for example "active ingredient" and "medicinal cannabis products", so classification under this specification depends on the enacted content of that subordinate instrument.

Mechanically, then, the instrument selects particular data fields about covered medicinal cannabis products for potential public release. The instrument does not set publication procedures, penalties for non-compliance, or specify any further categories of information beyond those listed in Schedule 1 (and parties should note the schedule as printed in this instrument lists items (a)-(e) only). The definitions for categories 1-5 are expressed as compositional thresholds and a negative requirement (no other active ingredient), so the categorisation outcome for a given product depends on laboratory-determined total cannabinoid composition and on the absence of other active constituents (clause 4).

The instrument directly affects three groups by defining what information may be published in relation to certain medicinal cannabis products; it indirectly affects additional stakeholders through expected downstream effects.

Directly affected parties

• The Secretary of the Department of Health: The instrument authorises the Secretary to release the specified kinds of therapeutic goods information under subsection 61(5C) of the Therapeutic Goods Act 1989 (clause 5; note to clause 5). The Secretary therefore decides whether, when and how to publish the specified fields, subject to any constraints in the Act itself. The instrument does not create a statutory duty beyond the power to release; it specifies the kinds of information that can be released.
• Sponsors of medicinal cannabis products: The Schedule identifies "sponsor name" as a specified kind of information for publication in relation to medicinal cannabis products that are subject to an authorised prescriber authority or a SAS B approval (Schedule 1, Item 1(e)). Where a product falls within the instrument's scope, a sponsor’s identity is within the universe of potential public disclosures authorised by the instrument.
• Authorised prescribers and SAS B applicants/recipients: The instrument targets products that are the subject of an "authorised prescriber authority" or a "SAS B approval" (Schedule 1, Item 1). Those who hold or administer such authorities or approvals , principally medical practitioners authorised under s 19(5) or parties using or obtaining approvals under paragraph 19(1)(a) , will be the focal point for any public data output because the instrument ties disclosure to those approval pathways. The instrument does not itself require prescribers to supply information; it only permits the Secretary to publish the listed fields.

Indirectly affected parties

• Patients and the public: The kinds of information listed , product name, active ingredient, dosage form, relevant category, sponsor name , are public-facing data points. If released, they could be used by patients, carers, clinicians, journalists and researchers. The instrument therefore affects information availability for those groups.
• Manufacturers, importers and distributors: Because the instrument identifies specific technical attributes (active ingredient, dosage form, relevant cannabinoid category) that may be published, manufacturers and supply-chain actors whose products are subject to authorised prescriber authorities or SAS B approvals may see more product-specific public transparency, with potential commercial and reputational implications.
• Consultants and advisers: Lawyers, compliance officers and in-house counsel advising sponsors or prescribers will need to consider how the specified information interacts with confidentiality and commercial information protections, and prepare clients for possible disclosure.

Who does not have new legal duties imposed by this instrument

• The instrument does not create new statutory duties on sponsors, prescribers or applicants to supply the information to the Secretary; it specifies what the Secretary may publish (clause 5; Schedule 1). It also does not itself create offences, set fees, or regulate manufacturing, supply or prescribing , those matters remain governed by the Act and Regulations.

Geographical and subject-matter limits

• The instrument is framed under the Therapeutic Goods Act 1989 and targets medicinal cannabis products as defined in the Regulations (clause 4). Thus, products outside the Act’s definition of "medicinal cannabis products" or outside the regulated supply pathways (registered goods, listed goods, exempt goods) will not be within the instrument unless they are the subject of the specified approvals or authorities. The scope therefore depends on regulatory definitions in the Regulations and on the product’s status under the Act.

This specification is not a normative instrument that imposes new duties on regulated parties; it operates by authorising the Secretary to release certain kinds of information. Nonetheless, it creates practical rights and potential exposures that parties should understand.

Duties created or affected by the instrument

• No direct new compliance duties on sponsors or prescribers: The instrument does not prescribe actions that sponsors, manufacturers, authorised prescribers, or applicants must take. It does not amend prescribing rules, manufacturing standards, or approval criteria. There is no clause in the instrument that requires third parties to deliver data to the Secretary because the instrument’s function is to specify what types of therapeutic goods information the Secretary may release (clause 5; Schedule 1).
• Secretary’s discretion to publish: The instrument confers, by reference to s 61 of the Act, an entitlement for the Secretary to release the specified fields in relation to medicinal cannabis products that are the subject of an authorised prescriber authority or a SAS B approval (clause 5; Schedule 1). The instrument does not define limits on the Secretary’s exercise of that release power beyond the listed kinds.

Rights effected or implicated

• Public right to information: By specifying the kinds of therapeutic goods information that may be released, the instrument enlarges the class of product-related data that the Secretary is authorised to make available to the public under the Act (clause 5; Schedule 1). The instrument therefore operationalises a public information right under the Act for those specified data fields.
• Sponsor identification: The inclusion of "sponsor name" in Schedule 1 (Item 1(e)) means that sponsors may be publicly identified in relation to medicinal cannabis products that are subject to authorised prescriber authorities or SAS B approvals. That is not a right or duty imposed on sponsors by the instrument, but it is an outcome that affects their public profile.

Constraints and definitional duties

• Categorisation by cannabinoid composition: The five "relevant category" definitions impose a technical rule for classification , each category is defined by precise percentage ranges of cannabidiol versus other cannabinoids and by the requirement that the medicine contain no other active ingredient (clause 4, definitions of category 1-5). Entities seeking to predict whether a product is within a specific category will need to rely on labelling, analytical testing and the Regulations’ definitions (the instrument ties "active ingredient" and "medicinal cannabis products" back to the Regulations) to determine the product’s classification.
• Dependence on Act provisions for scope: The instrument’s effect depends upon the existence of an authorised prescriber authority (subsection 19(5) of the Act) or a SAS B approval (paragraph 19(1)(a) of the Act) for the relevant product (clause 4; Schedule 1). Parties therefore have a working duty to understand whether a product is subject to such an approval or authority under the Act, because only those products are within the instrument’s publication scope.

Absence of enforcement provisions

• No penalties or enforcement mechanisms are created by the specification. It does not create offences for non-disclosure by third parties or for the publication of specified fields; nor does it create sanctions for the Secretary’s failure to publish. Any enforcement or penalty rules would arise from the Act itself, not from this instrument.

Practical implication for regulated parties

• While no new statutory duties are imposed on ministers, sponsors or prescribers, the instrument creates an operational expectation: certain product-level data points about medicinal cannabis products that are the subject of specific approvals or authorities are within the subset of therapeutic goods information that the Secretary may publish. Parties should therefore treat those fields as potentially public and consider confidentiality and record-keeping strategies accordingly.

This instrument does not create penalties, enforcement mechanisms, or criminal civil sanctions. It is a specification made under subsection 61(5D) of the Therapeutic Goods Act 1989 that identifies kinds of therapeutic goods information the Secretary may publish; it neither creates offences nor prescribes enforcement processes.

What the instrument says about enforcement

• No penalties in the instrument itself: The text contains no offence provisions, monetary penalties, or administrative sanctioning mechanisms. The instrument is framed solely as a specification for the purpose of s 61(5C) of the Act (clause 5), and the Schedule lists kinds of information. There is no clause establishing investigatory powers, auditing powers, inspection powers, or enforcement remedies.
• Secretary’s discretion not bound by instrument text: The specification authorises potential public release; it does not compel publication or prescribe how the Secretary must publish or manage disclosures. The instrument therefore leaves operational enforcement and compliance measures, if any, to the Act and to the Secretary’s policies or administrative processes.

Interplay with the Act’s enforcement machinery

• Release under s 61 may be subject to the Act’s wider provisions: The instrument is made under subsection 61(5D) and defined for subsection 61(5C) purposes (clause 3; clause 5). Any penalty or sanction regime that may apply in relation to the unauthorised or improper release of therapeutic goods information would be governed by the Act’s general provisions or by other Commonwealth legislation, not by this specification itself. Because the instrument does not alter the Act’s enforcement framework, readers should consult the Act for any statutory offences or liabilities that might relate to disclosure, misuse or protection of therapeutic goods information.

Administrative risk management

• No administrative enforcement prescription: Administrative practices for publishable data, information management, redaction, or consultation with affected parties are not provided in the instrument. The Secretary will have discretion to determine publication process and redaction practices, subject to the Act and any other applicable laws. The instrument does not require consultation or notice to sponsors or prescribers before publication; any such practice would be an operational matter under the Secretary’s discretion rather than a statutory duty established here.

Potential exposure without statutory penalties

• Although the instrument itself does not create penalties, the practical exposure for affected parties is reputational and commercial rather than criminal or civil under this instrument. The Schedule’s inclusion of fields such as sponsor name and product name means that, if the Secretary elects to publish them, sponsors and related entities will be publicly identified. The instrument does not provide remedies or specify how disputes about accuracy of published information will be resolved; those matters would be managed under other parts of the Act or administrative procedures.

Advice point for practitioners

• Because the instrument is silent on enforcement measures and on protective procedures for third-party interests (for example, confidentiality safeguards or correction mechanisms), parties with potential exposure should assume publication is possible and seek to manage operational risks (records, labelling, engagement with the Secretary) through non-legislative means and by reference to the Act and departmental policies.

The instrument situates itself within the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 by explicit cross-reference. Beyond that, the instrument is silent. The interaction with other statutes and legal regimes will therefore depend on the contents and operation of those other laws; the instrument itself neither declares nor limits those interactions.

Express statutory cross-references in the instrument

• Therapeutic Goods Act 1989: The instrument is made under subsection 61(5D) of the Act (clause 3) and expressly references other Act provisions in its definitions: "authorised prescriber authority" is defined by reference to subsection 19(5) and "SAS B approval" by reference to paragraph 19(1)(a) (clause 4). Clause 5 ties the Schedule expressly to subsection 61(5C) (clause 5; note to clause 5). The instrument therefore operates as a subordinate instrument under the Act and must be read against the Act’s information-release framework.
• Therapeutic Goods Regulations 1990: Several defined terms are said to have the "same meaning as in the Regulations" (for example, "active ingredient" and "medicinal cannabis products") (clause 4). The categorisation of products as "medicinal cannabis products" or the proper interpretation of "active ingredient" depends on the Regulations’ definitions and standards; the instrument does not displace or alter those definitions.

Matters the instrument does not address and that may engage other laws

• Privacy and personal information laws: The instrument authorises the public release of some product-level fields (product name, sponsor name, active ingredient, dosage form, relevant category) (Schedule 1, Item 1(a)-(e)). It does not address personal information or patient-identifying data. The instrument is silent on whether disclosure of the specified fields must be reconciled with the Privacy Act 1988 or other privacy law obligations when publication could incidentally reveal personal data. Practitioners should therefore assess whether any release under the Act might intersect with privacy obligations in other legislation or administrative policy.
• Commercial confidentiality and trade secrets: The instrument makes no express provision for protecting commercially sensitive information. The specified fields do include sponsor identity and product attributes; however, the instrument does not create exemptions for commercially sensitive data. Parties concerned with commercially confidential information will need to consider whether other statutory regimes, contractual terms, or administrative processes within the Department impose protections that limit disclosure.
• Freedom of information and administrative law: The instrument does not engage FOI directly but sits within administrative law. Requests for non-specified kinds of therapeutic goods information, or disputes about the Secretary’s use of the release power, would be addressed under administrative law principles, FOI legislation or under the Act’s own access and review mechanisms. The instrument does not create or foreclose FOI rights; it only identifies which kinds of therapeutic goods information the Secretary may release under the Act.
• Criminal and civil liability regimes: The instrument contains no provisions that displace or modify liabilities under other Commonwealth, State or Territory laws (for example, laws governing controlled substances, advertising, or product liability). Those regimes remain in force and may be relevant where publication touches on regulated matters beyond the Act’s information-release power.

Practical interaction points

• Reliance on Regulations: Because key terms are tied back to the Regulations (clause 4), the classification of a product for the purposes of this instrument will in practice require cross-checking the Regulations. This creates a necessary interaction: the instrument’s scope is dependent on the content of the Regulations.
• Secretary’s administrative policies and procedures: The instrument authorises release under the Act but does not set procedural rules. Any procedural or protective rules that affect how the Secretary publishes the specified kinds of information will be determined by departmental policy, administrative practice and the Act itself. These practices in turn may need to reconcile with privacy law, commercial confidentiality, FOI, and administrative law principles.
• No express conflict resolution mechanism: The instrument does not specify how conflicts between this specification and other obligations (for example, contractual confidentiality clauses or regulatory secrecy obligations) are to be resolved. That leaves the interaction to be handled by the Act’s framework, administrative processes, or by legal challenge under administrative law where appropriate.

In summary, the instrument operates as a narrow, subordinate specification under the Therapeutic Goods Act and the Regulations. Its practical effect in relation to other laws depends largely on how the Secretary exercises the release power and on the content of the Regulations and other statutory regimes that govern privacy, confidentiality and controlled substance regulation.

The instrument itself records minimal internal amendment history and contains a commencement table with a procedural note. All specifics in the instrument about timing, authority and structure are self-contained.

Instrument provenance and date

• Dated and signed: The instrument is dated 19 November 2021 and is signed by Dr Jane Cook, First Assistant Secretary, Medicines Regulation Division, Health Products Regulation Group, Department of Health (instrument header).
• Commencement: Clause 2 sets the commencement rule. Clause 2(1) contains a table stating that "the whole of this instrument" commences "The day after this instrument is registered." The instrument notes that the table relates only to the provisions "as originally made" and will not be amended to deal with later amendments (clause 2(1)-(2)). The instrument therefore commenced the day after registration in 2021.

Authority for amendment

• Made under s 61(5D): Clause 3 records the legal authority: "This instrument is made under subsection 61(5D) of the Therapeutic Goods Act 1989." That subsection empowers the Minister to specify kinds of therapeutic goods information for release under the Act. Amendment of the instrument would similarly require the authorised delegate or Secretary acting under the same statutory power, unless the Act is amended to alter the power.

Notes about the published instrument and editorial fields

• Column 3 in the commencement table: Clause 2(2) states explicitly that any information in column 3 of the commencement table is not part of the instrument and may be edited in any published version. This is an editorial construct and indicates that published or online versions may contain additional non-legally-binding editorial material.

Absence of recorded amendments in the text provided

• No subsequent amendments recorded: The text supplied contains no additional notes about later amendments, revocations, or superseding instruments. There is no consolidated amendment history in the instrument text provided. Any amendment history beyond the original instrument is therefore not present in this document.

Practical consequence for users

• Check for newer instruments or amendments: Because the instrument itself does not archive later amendments in the table and because the supplied text contains only the original instrument, practitioners should verify in official legislative databases whether the instrument has been amended, revoked, or superseded since 19 November 2021. The instrument’s own text cautions readers that the commencement table relates only to the original making; it says nothing about later amendment practice or possible repeals.

The instrument contains no case law references and records no litigation or judicial consideration. The text supplied contains no indication that it has been the subject of judicial review or other litigation.

What the instrument itself records

• No litigation references in the text: There are no mentions of decisions, appeals, tribunal proceedings, or other legal contests in the instrument text. The instrument is a specification of kinds of information and does not include transitional or contested legal material.

Implications for practitioners seeking precedent

• No directly attributable litigation precedent from this instrument: Because the instrument is purely declarative and administrative in character, and because the supplied text contains no reported disputes, there is no litigation history to cite from the instrument itself. Any judicial review or litigation that engages the Secretary’s exercise of the s 61 release power or that challenges a particular disclosure would be reported elsewhere and is not recorded in this instrument.

Points of likely legal contention (theoretical and subject to actual cases)

• Potential grounds for litigation would be administrative law challenges to the Secretary’s exercise of the power to publish specific data, or challenges invoking privacy or confidentiality rights in relation to specific disclosures. The instrument itself does not create such cases; it only sets out the kinds of information that may be released. Any litigation history therefore would arise from specific factual releases and the Department’s handling of those releases, not from the specification as a text.

Recommendation for legal research

• If judicial authority is required for advice, search for decisions dealing with: (a) the Secretary’s use of subsection 61(5C) to publish therapeutic goods information; (b) disputes over disclosure of sponsor identity or product details under the Act; and (c) any conflicts between the Act’s disclosure regime and privacy or confidentiality laws. The instrument itself contains no litigation history and so is not a source of precedent beyond the statutory text and the specified fields.

This instrument is short and tightly targeted, but that narrowness contains several practical pitfalls and traps for users who do not read the text carefully. Below are concrete gotchas, each referenced to the instrument text.

1. The Schedule appears limited and literal

• The Schedule lists only five specified fields , active ingredient, dosage form, product name, relevant category, sponsor name , and only in relation to products "that are the subject of an authorised prescriber authority or a SAS B approval" (Schedule 1, Item 1). Do not assume the Secretary may publish other fields (batch numbers, dates of approval, prescriber identity, patient data) merely because they are "therapeutic goods information". The instrument specifies only the listed kinds for the purpose of subsection 61(5C) (clause 5; Schedule 1).

2. The definitions of categories are technical and exclusive

• The "relevant category" definitions (category 1-5) are precise percentage-ranged definitions based on total cannabinoid content and require that the medicine contain "no other active ingredients" (clause 4). A product that contains any other active ingredient falls outside these categories irrespective of cannabinoid ratios. Practitioners should not assume that a product with, for example, an added analgesic is within category 1-5.

3. "Active ingredient" and "medicinal cannabis products" are defined elsewhere

• The instrument says "active ingredient has the same meaning as in the Regulations" and that "medicinal cannabis products has the same meaning as in the Regulations" (clause 4). Therefore, whether a specific product falls within the instrument’s scope depends on the Therapeutic Goods Regulations 1990 , check those Regulations carefully. Misreading the instrument without checking the Regulations is a common hazard.

4. The instrument ties disclosure to specific approval pathways

• Information release is explicitly linked to products that are the subject of an authorised prescriber authority (s 19(5)) or a SAS B approval (paragraph 19(1)(a)) (Schedule 1, Item 1; clause 4 definitions). Products that are, for instance, registered, listed, or exempt might be outside the publication scope unless they also happen to be the subject of the specified approvals. Do not assume all medicinal cannabis products are covered.

5. No procedure, no notice, no remedies in the instrument

• The instrument does not require the Secretary to notify sponsors or prescribers prior to publication, nor does it provide a correction, redaction, or appeal mechanism in respect of published items. If publication occurs, remedies or dispute resolution would need to be sought under the Act, administrative law, or other applicable statutes , the instrument itself provides none.

6. Sponsor name disclosure is authorised

• The inclusion of "sponsor name" among the specified kinds is material: if the Secretary publishes the listed items, sponsors may be identified publicly in relation to the given approvals or authorities (Schedule 1, Item 1(e)). Sponsors should not assume confidentiality in everything solely because a product is supplied under a SAS B approval or authorised prescriber pathway.

7. The instrument does not create new offences or penalties

• Because the instrument contains no enforcement or penalty provisions, affected parties should not expect a statutory remedy or a penalty regime arising from this specification itself. Issues concerning misuse of published data or unlawful disclosure would rely on other statutes or administrative remedies.

8. The instrument is concise and depends on the Act

• The specification’s legal effect is derivative , it operates only by virtue of s 61 of the Act. Any assumptions about the effect of publication, limits to publication, or obligations triggered by publication must be checked against the Act and any relevant Regulations and departmental policies. The instrument does not expand or contract the Act’s publication power beyond naming the kinds of information.

9. Editorial note about commencement table

• Clause 2(2) warns readers that information in column 3 of the commencement table is not part of the instrument and may be edited in published versions. Do not rely on editorial notes in published versions as legally operative parts of the instrument.

10. Truncation or transcription risk

• The Schedule in the provided text ends with an open vertical bar after "sponsor name;" , practitioners should check the official published instrument for any additional items or precise punctuation that could affect interpretation. Rely on the official gazetted text if possible.

The instrument imposes no new statutory duties on sponsors, prescribers or applicants. Compliance, in practice, means preparing for the possibility that specific product-level fields may be published by the Secretary and managing the risks that follow. The steps below are practical and grounded in the instrument’s text (clause 5; Schedule 1; clause 4 definitions).

1. Identify whether your product is within scope

• Determine whether a product is a "medicinal cannabis product" as defined in the Therapeutic Goods Regulations 1990 (clause 4). Then confirm whether the product is the subject of an authorised prescriber authority (subsection 19(5) of the Act) or a SAS B approval (paragraph 19(1)(a) of the Act). Only products that meet both criteria (medicinal cannabis product and being subject to one of those approvals/authorities) fall within the publication scope in Schedule 1 (Schedule 1, Item 1).

2. Verify product categorisation against the instrument’s definitions

• To anticipate which "relevant category" the Secretary might publish, measure the product’s total cannabinoid content and apply the category thresholds in clause 4 (category 1-5). Ensure your analytical testing and product documentation can support categorisation, because the instrument’s category definitions hinge on precise percentage thresholds and on the absence of other active ingredients.

3. Audit your records and labelling

• Because Schedule 1 lists active ingredient, dosage form, product name and sponsor name (Schedule 1, Item 1(a)-(e)), ensure your product records, labelling and sponsor identity are accurate and defensible. The instrument authorises publication of those fields; inaccurate internal records or inconsistent labelling increase risk of misstatement in the public domain.

4. Consider confidentiality and commercial strategies

• Although the instrument does not provide confidentiality protections, the practical effect of possible public disclosure of sponsor identity and product attributes is commercial. Sponsors should review confidentiality clauses in contracts, consider IP protections, and plan communications strategies in case the Secretary publishes material that could affect market position.

5. Prepare an operational response plan

• Because the instrument does not specify procedures for publication or correction, have a plan in place for responding to a public release. That plan should designate who will:
  • verify accuracy of published entries;
  • contact the Department to request corrections if necessary;
  • manage media or customer inquiries arising from publication.

6. Liaise with legal and regulatory advisers

• Engage counsel or regulatory advisers to: (a) confirm whether a product is within the instrument’s scope; (b) prepare challenges or administrative enquiries if an erroneous publication occurs; and (c) advise on interaction with privacy, consumer law and confidentiality obligations that may be implicated by publication.

7. Monitor departmental publications

• The instrument authorises releases under subsection 61(5C); monitor Department of Health publications, registers and channels where the Secretary customarily publishes therapeutic goods information so you can spot any entries related to your products promptly.

8. Document approvals and prescriber authorities

• Maintain up-to-date documentation of any authorised prescriber authorities or SAS B approvals associated with your products. Because the instrument links publication to those approval pathways (Schedule 1, Item 1), clear records will help in any follow-up with the Department.

9. Check the Regulations and the Act for related obligations

• The instrument ties key terms back to the Regulations and the Act (clause 4). Ensure compliance with any labelling, reporting or notification obligations in the Regulations and the Act that may affect whether a product is covered or how its information is presented.

10. Be mindful of the limited content of this specification

• The instrument lists only specific fields. Do not assume that publication under this instrument will include broader datasets (for example, prescriber names, patient information, or clinical data) unless those data are separately authorised for release under the Act or other laws. If you require assurance about the scope of future releases, seek clarification from the Department.

Concluding operational pointer

• The instrument creates a manageable operational obligation: anticipate transparency. Sponsors and stakeholders should treat the Schedule’s fields as plausibly public information in the event of publication and organise accuracy verification, contractual confidentiality, and public relations procedures accordingly. The instrument itself imposes no disclosure duty on third parties, but it alters the information environment to which affected parties must respond.